Intercept Pharmaceuticals (ICPT) Financials
$19.00
$0.00 (0.00%)As on 14-Nov-2023 09:30EDT
Market cap
$795 Mln
Revenue (TTM)
$318 Mln
P/E Ratio
--
P/B Ratio
44.2
Div. Yield
0 %
Income Statement ($ Mln) |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
317.68
|
285.71
|
363.47
|
312.69
|
252.00
|
179.80
|
|||||
|
Cost of Revenue
|
0.63
|
0.98
|
3.10
|
5.32
|
4.21
|
2.52
|
|||||
|
Gross Profit
|
317.05
|
284.73
|
360.37
|
307.37
|
247.79
|
177.29
|
|||||
|
Operating Expenses
|
373.07
|
352.94
|
416.13
|
523.98
|
560.22
|
462.78
|
|||||
|
Operating Profit (EBIT)
|
-62.28
|
-68.22
|
-55.76
|
-216.61
|
-312.43
|
-285.49
|
|||||
|
Other Income
|
10.74
|
-85.26
|
18.67
|
4.41
|
8.89
|
6.77
|
|||||
|
Profit before Tax
|
-58.01
|
-174.86
|
-91.43
|
-274.88
|
-344.68
|
-309.24
|
|||||
|
Provision for Tax
|
8.62
|
-290.03
|
53.60
|
49.35
|
46.37
|
6.77
|
|||||
|
Profit after Tax (Net Income)
|
-58.61
|
115.17
|
-145.02
|
-324.23
|
-391.05
|
-309.24
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
-58.82
|
221.82
|
-91.43
|
-274.88
|
-344.68
|
-309.24
|
Liabilities ($ Mln) |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
71.85
|
93.08
|
-183.96
|
-166.85
|
51.56
|
19.13
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
230.47
|
230.56
|
544.17
|
568.27
|
541.33
|
375.83
|
|||||
|
Current Liabilities
|
90.85
|
230.08
|
166.82
|
179.08
|
162.01
|
114.21
|
|||||
|
Total Liabilities
|
484.01
|
553.71
|
527.02
|
580.49
|
754.89
|
509.17
|
Assets ($ Mln) |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
9.72
|
13.58
|
24.73
|
103.32
|
33.57
|
26.74
|
|||||
|
Current Assets
|
383.45
|
540.13
|
502.29
|
477.17
|
721.32
|
482.43
|
|||||
|
Total Assets
|
484.01
|
553.71
|
527.02
|
580.49
|
754.89
|
509.17
|
|||||
|
Total Debt*
|
223.86
|
332.67
|
547.21
|
575.51
|
538.53
|
453.74
|
|||||
|
Net Current Assets
|
292.60
|
310.05
|
335.48
|
366.67
|
559.31
|
368.22
|
Cashflow ($ Mln) |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-26.78
|
-41.64
|
-170.03
|
-236.61
|
-240.71
|
|||||
|
Cash Flow from Investing Activities
|
--
|
261.85
|
70.73
|
162.82
|
-188.99
|
-48.07
|
|||||
|
Cash from Financing Activities
|
--
|
-267.32
|
1.12
|
-0.69
|
457.52
|
263.55
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
-32.25
|
30.21
|
-7.90
|
31.92
|
-26.77
|
Financials Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-1.41
|
2.78
|
-4.91
|
-9.82
|
-11.93
|
-10.42
|
|||||
|
Cash EPS ($)
|
--
|
2.79
|
-4.80
|
-9.73
|
-11.82
|
-10.27
|
|||||
|
Adjusted Book Value ($)
|
--
|
2.24
|
--
|
--
|
1.57
|
0.64
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
-0.65
|
-1.41
|
-5.15
|
-7.22
|
-8.11
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
-0.66
|
-1.42
|
-5.27
|
-7.25
|
-8.12
|
Profitability Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
29.20
|
-37.57
|
-64.93
|
-73.58
|
-73.20
|
|||||
|
ROE (%)
|
-84.31
|
-253.45
|
82.68
|
562.43
|
-1,106.45
|
-1,741.42
|
|||||
|
ROA (%)
|
-9.27
|
21.31
|
-26.19
|
-48.56
|
-61.87
|
-62.25
|
|||||
|
EBIT Margin (%)
|
-16.56
|
-23.88
|
-15.34
|
-69.27
|
-123.98
|
-157.56
|
|||||
|
Net Margin (%)
|
-17.85
|
57.46
|
-37.95
|
-102.25
|
-149.89
|
-165.75
|
|||||
|
Cash Profit Margin (%)
|
0.00
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-3.83
|
-0.21
|
0.16
|
0.24
|
0.40
|
0.37
|
|||||
|
EBIT Growth (%)
|
4.63
|
-22.34
|
74.26
|
30.67
|
-10.28
|
15.61
|
|||||
|
Net Profit Growth (%)
|
-159.53
|
179.42
|
55.27
|
17.09
|
-26.46
|
14.19
|
|||||
|
EPS Growth (%)
|
-155.73
|
1.57
|
0.50
|
0.18
|
-0.14
|
0.27
|
|||||
|
Book Value Growth (%)
|
-45.25
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
4.45
|
-3.32
|
-2.51
|
-10.39
|
-9.67
|
|||||
|
Price / Book Value
|
44.19
|
5.51
|
-2.62
|
-4.89
|
78.79
|
156.34
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
-3.59
|
-5.84
|
-11.36
|
-4.34
|
-13.01
|
-9.38
|
|||||
|
Close Price ($)
|
18.54
|
12.37
|
16.29
|
24.70
|
123.92
|
100.79
|
|||||
|
High Price ($)
|
21.86
|
21.25
|
38.94
|
121.53
|
131.87
|
133.74
|
|||||
|
Low Price ($)
|
8.82
|
10.81
|
11.60
|
24.25
|
56.76
|
51.05
|
|||||
|
Market Cap ($ Cr)
|
794.69
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
3.12
|
3.57
|
-2.97
|
-3.45
|
10.45
|
23.72
|
|||||
|
Short term debt to equity ratio
|
--
|
1.18
|
-0.02
|
-0.04
|
0.13
|
4.31
|
|||||
|
Current Ratio
|
4.22
|
2.35
|
3.01
|
2.66
|
4.45
|
4.22
|
|||||
|
Quick Ratio
|
4.19
|
2.32
|
2.96
|
3.05
|
4.40
|
4.16
|
|||||
|
Interest Coverage
|
-4.81
|
-3.19
|
-1.02
|
-4.51
|
-7.59
|
-9.28
|
Operating Efficiency Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
10.22
|
9.40
|
13.10
|
13.29
|
15.10
|
14.29
|
|||||
|
Asset Turnover
|
0.50
|
0.53
|
0.66
|
0.47
|
0.40
|
0.36
|
|||||
|
Receivable days
|
--
|
47.61
|
44.80
|
46.49
|
46.19
|
44.96
|
|||||
|
Inventory Days
|
--
|
2,798.95
|
-3,531.85
|
-2,062.65
|
675.09
|
767.62
|
|||||
|
Payable days
|
--
|
6,006.95
|
2,517.04
|
1,495.07
|
1,332.83
|
1,357.91
|
|||||
|
Cash Conversion Cycle
|
--
|
-3,160.39
|
-6,004.09
|
-3,511.24
|
-611.55
|
-545.33
|